Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company provides SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.…
BetterInvesting™ Magazine Update on Electromed Inc. and Five Below Inc.
Electromed (NYSEAMERICAN: ELMD) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 195 employees.
The shares were at 22.98 USD on 20 November 2026, down 6.0% over 52 weeks. Its 52-week range is 22.72 USD to 47.38 USD: the price is 51.5% below the high and 1.1% above the low.
At a market capitalisation of 187.84M USD, it trades at 16.7 times trailing earnings and 37.7 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 35% for ELMD.
Electromed reports return on equity of 20.9%, an operating margin of 19.5% and revenue up 10.6% year over year.
It holds more cash than debt, a net cash position of 15.82M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 48.50 USD is 111.1% above the current price. The next earnings report is expected on 9 February 2027.